M&A Deal Summary |
|
|---|---|
| Date | 2020-09-01 |
| Target | Flaskworks |
| Sector | Medical Products |
| Buyer(s) | Northwest Biotherapeutics |
| Deal Type | Add-on Acquisition |
| Deal Value | 4M USD |
SEARCH BY
Northwest Biotherapeutics, Inc. is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 2 |
| State: Massachusetts M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2020 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-08-27 |
Advent Bioservices
Cambridge, United Kingdom Advent Bioservices is a cell therapy Contract Development & Manufacturing Organisation (CDMO) that manages the development of a state-of-the-art facility for multiproduct Good Manufacturing Practice (GMP) production outside Sawston in Cambridgeshire, which will allow scale-up of current commercial production and initiate the provision of contract manufacturing services to meet the growing demand for such services in the UK. Advent Bioservices was formed in 2016 and is based in Cambridge, United Kingdom. |
Buy | - |
